Kornimate/medical-research-clean huggingface dataset:
screening & health education in barbershop centers for hypertension

Conditions: Hypertension

Summary: saloon-htn is a cross-sectional, descriptive, non-interventional, multicenter survey aiming to screen high blood pressure by measuring blood pressure in barbershops.

the survey is a screening project for hypertension, which will enroll subjects at the barbershops. the metline township (located at bizerte town, in the north of tunisia) will be the geographical area of population enrollment. barbershops hairdressers will be trained by a medical staff to measure the blood pressure by an ambulatory device. all subjects willing to participate in the survey will be asked to measure their blood pressure by after at least 5 minutes rest. three measures will be performed by the hairdressers, with an interval of 3 minutes between each measure. the mean of the last two measures will be considered. if the mean blood pressure level exceeds 135/85 mmhg the subject will be sent to a physician of his choice.

Eligibility criteria:
inclusion criteria: * age \> 18 years old * informed consent to participate in the screening study exclusion criteria: * none

Keywords: barbershop screening health education cardiology dacima clinical suite
pilot study of hippocampal function in type 1 diabetes mellitus (t1dm)

Conditions: Type 1 Diabetes Mellitus

Summary: this study is an expansion of a previous study done to determine how thinking skills relate to hypoglycemia (low blood sugar) and certain regions of the brain in children and adolescents. in this study, the investigators are testing thinking skills and measuring brain activity in adolescents with and without type 1 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * age 13 - 18 * right handed * diagnosis of type 1 diabetes or normal sibling control * if diabetic, then diagnosis for at least 2 years exclusion criteria: * pregnant or lactating * chronic disease other than well-controlled asthma, or hashimoto's thyroiditis. * other current serious medical illness * co-morbid psychiatric illness * co-morbid neurological illness * pre-maturity at birth * contraindication to mri scan * orthodontic braces.

Keywords: t1dm mri
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosome intranasal instillations for stroke

Conditions: Stroke

Summary: this trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of stroke

this patient funded trial aims to study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell (uc-msc) exosomes for the treatment of stroke. patients will receive intranasal instillations between both nasal cavities of uc-msc exosomes. the total dose will be 4 cc of alloex, approximately 800 billion exosomes, for each day. patients will receive instillations on back-to-back days totaling 2 doses. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. for patients with more severe disease an autologous effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: stroke stem cell treatment
a exploratory study of kwa-0711 in patients with chronic idiopathic constipation (cic)

Conditions: Chronic Idiopathic Constipation

Summary: the purpose of this study is to evaluate the efficacy and safety of kwa-0711 in chronic idiopathic constipation (cic) patients.


Eligibility criteria:
inclusion criteria: * the patients who experienced fewer than three sbms per week for more than 6 months prior to the enrollment * the patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation exclusion criteria: * patients who have secondary constipation caused by systemic disorder * patients who have organic constipation * patients who received intestinal resection

Keywords: chronic idiopathic constipation (cic) constipation functional gastrointestinal disorders
ketogenic diet and chemotherapy in affecting recurrence in patients with stage iv breast cancer

Conditions: Stage IV Breast Cancer AJCC v6 and v7

Summary: this pilot clinical trial studies how well a ketogenic diet and chemotherapy work in affecting the return of cancer in patients with stage iv breast cancer. ketogenic diet may be more effective than standard nutrition and may affect quality of life, inflammation, and tumor-related changes. drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. giving ketogenic diet and chemotherapy may be better in patients with breast cancer.

primary objectives: i. to evaluate the feasibility of implementing a diet that induces nutritional ketosis in women who are initiating palliative chemotherapy to treat advanced stage breast cancer (bc). ii. to determine the effects of a ketogenic diet on tumor progression. iii. to determine the effects of nutritional ketosis on biologic and behavioral health markers. outline: patients are assigned to 1 of 2 arms. arm i: patients receive standard of care therapy with paclitaxel. arm ii: patients receive standard of care with paclitaxel. patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>= 22 kg/m\^2 * confirmed diagnosis of metastatic or stage iv bc * fludeoxyglucose f-18 (fdg)-positron emission tomography (pet) avid tumors * eastern cooperative oncology group (ecog) performance status of 0-1 (0=participant has either normal activity, 1= participant has some symptoms but is nearly full ambulatory) * life expectancy \> 6 months * able and willing to follow prescribed diet intervention exclusion criteria: * prior chemotherapy for metastatic breast cancer (mbc) (prior adjuvant chemotherapy permitted as long as \> 12 months \[mo\]) * bmi \< 25 kg/m\^2 * weight change \> 5% within 3 months of enrollment * type 1 diabetes * history of diabetes with retinopathy requiring treatment * current use of insulin or sulfonylureads for glycemic control, or history of ketoacidosis * intestinal obstruction * bilirubin \> 2 * albumin \< 3.5 * glomerular filtration rate (gfr) \< 55 ml/min * creatinine \> 2.0 * urinary albumin \> 1 g/day * congestive heart failure * pregnant or nursing women * unable to provide informed consent * uncontrolled concurrent medical conditions that would limit compliance with study requirements
phase i, dose-escalation study of dihydromyricetin (dhm) to treat alcohol-associated liver disease

Conditions: Alcohol-Related Disorders

Summary: the current proposal is designed as a first-in-human phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of dhm among healthy volunteers using a purified form of dhm from a local cgmp compliant source (master herbs, inc).

dihydromyricetin (dhm), a bioactive flavonoid from an edible plant (ampelopsis grossedentata), is reported to have multiple protective effects against chemical-induced liver injuries. for example, the antioxidant activity and cellular metabolic protective effects of dhm may act via the amp kinase (ampk) and nicotinamide adenine dinucleotide (nad+)-dependent sirtuin (sirt)-1 energy regulating pathway. furthermore, there is accumulating evidence supporting the use of dhm for the treatment of alcohol use disorder and the possible reduction/prevention of alcohol-associated liver disease in animal models. dhm may represent a novel approach to counteract alcohol-induced liver damage and promote alcohol metabolism via changes in hepatocellular bioenergetics and mitochondrial biogenesis driven by the ampk/sirt-1/pgc-1α axis. these preclinical data suggest the potential of dhm as a novel therapeutic agent in alcohol-related diseases. however, further study in humans is warranted. while dhm has been used for herbal tea in traditional chinese medicine for hundreds of years, and there has been a small clinical trial using dhm in china among individuals with non-alcoholic fatty liver disease, there have been no controlled human studies published that have assessed the safety, pharmacokinetics, or optimal dosing of dhm in humans. dhm is marketed as a dietary supplement in the united states and is not regulated by the food and drug administration (fda) as a drug. because the fda has little control over the quality of herbal products such as dhm, it is necessary to quantitatively estimate the potentially active ingredients and the pharmacokinetic (pk) profile with oral administration. the current proposal is designed as a first-in-human phase 1 open-label, dose-escalation study to assess the safety, pharmacokinetics, and the maximum tolerated dose of dhm among healthy volunteers using a purified form of dhm from a local cgmp compliant source (master herbs, inc).

Eligibility criteria:
inclusion criteria: * no prior medical history of alcohol use disorder or alcohol-associated liver disease * between 18-60 years old exclusion criteria: * weight below 50kg. * advanced liver disease * other acute liver diseases * hiv co-infection * history of pancreatic or biliary disease * acute illness that would interfere with drug absorption * pregnancy * participants who are currently taking drugs with cyp3a4 effects * fib-4 index \> 1.30 * history of alcohol use disorder (aud) determined by score \> 8 on audit questionnaire
evaluation of left ventricular autothreshold

Conditions: Heart Failure

Summary: this study will collect data on a new feature for future heart failure devices via an external non-implantable system.

elevate is an acute, prospective, multi-center, feasibility study with a randomized within patient test sequence and pulse width, designed to characterize the performance of the left ventricular auto threshold feature.

Eligibility criteria:
inclusion criteria: * patients who are scheduled to receive a crt-p or crt-d, based on physician discretion * patients who are willing and capable of participating in all testing associated with this study * patients who are 18 or above, or of legal age to give informed consent specific to state and national law exclusion criteria: * patients who have, or are scheduled to receive a unipolar lv pace/sense lead to be used with the crt-p/crt-d device, unless the patient has any commercially available epicardial leads with at least two electrodes (from one or more leads) * patients with pre-existing leads other than those specified in this investigational plan (unless the investigator intends to replace them with permitted leads) * patients with a pre-existing unipolar pacemaker that will not be explanted/abandoned * patients enrolled in any concurrent study, without boston scientific crm written approval, that may confound the results of this study * patients with a prosthetic mechanical tricuspid heart valve * women who are pregnant

Keywords: heart failure auto threshold pacing crt-p or crt-d recipients, threshold measurements
study of long-term use of proton-pump-inhibitors in general practice

Conditions: Dyspepsia; Gastroesophageal Refluxdisease; Ulcer

Summary: the primary purpose of the study is to determine the effect of esomeprazole compared to placebo in patients from general practice who have previously been treated with proton-pump-inhibitors (ppi) and who have no upper endoscopic findings.

the majority of patients with dyspepsia are treated in primary care with acid-suppressive therapy for shorter or longer periods of time on the assumption that the patients´ symptoms are related to the production of acid in the stomach. in about half of the dyspeptic patients there is no structural or biochemical explanation for their symptoms. these patients suffer from functional dyspepsia. treatment with proton-pump-inhibitors is effective in treating patients with gastroesophageal refluxdisease or ulcers. it is however controversial if acid-suppressive treatment is effective in the large group of patients with functional dyspepsia. previous studies have shown no or very modest effect with a very high placeboresponse rate of 40-50%. in primary care patients with upper abdominal symptoms are often treated with ppi as a diagnostic tool. if the treatment is effective continued or repeated treatment with ppi is often favored. however some of the patients must experience the abovementioned placebo-effect. these patients may end up being treated with ppi long-term on uncertain indication. we wish to investigate the consequences of withdrawing treatment with ppi in patients from general practice who have previously been treated long-term. an upper endoscopy is performed in patients who experience upper abdominal symptoms after withdrawal of treatment.if the endoscopy is normal patients are randomised to 1 week treatment with either esomeprazole or placebo.

Eligibility criteria:
inclusion criteria: * treatment with ppi in at least 4 months out of the preceding 12. * use of ppi in the preceding 10 out of 30 days before inclusion * age above 18 years exclusion criteria: * erosive esophagitis * ppi-treatment as prophylaxis against gastrointestinal bleeding * ppi-treatment as prophylaxis against ulcers * ppi-treatment as prophylaxis because of nsaid-treatment * pregnant or lactating women * previous upper gi surgery

Keywords: protonpumpinhibitors withdrawal longterm treatment dyspepsia functional dyspepsia gastrooesophageal reflux upper endoscopy
secondary prophylaxis of cmv infection using letermovir after hid-hsct

Conditions: To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation

Summary: to evaluate the efficacy and safety of secondary prophylaxis of cmv reactivation, clinically significant cmv infection with oral letermovir in chinese haplo-hsct patients, as well as treatment-related mortality, all-cause mortality and qol after transplantation. for enrolled patients, letermovir would be administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). the regimen duration of dosing was approximately 120 days or 16 weeks. or physicians could adjust regimen duration according to the cmv infection risk factors.


Eligibility criteria:
inclusion criteria: - (1) underwent hla-haploidentical donor hsct, after at least 1 treated cmv episode since transplant in patients who did not receive primary prophylaxis. (2) age elder than or equal to 18 years; (3) informed consent may be signed by themselves. (4) hiv negative, hbv, hcv negative; (5) informed consent must be signed before the start of the study procedures, and informed consent must be signed by the patient himself or his immediate family. considering the patient 's condition, if the patient' s signature is unfavorable for disease treatment, the informed consent form should be signed by the legal guardian or the patient 's immediate family member exclusion criteria: * (1) received a previous allogeneic hsct; (2) has evidence of cmv viremia from a central or local laboratory, or cmv end-organ disease within one week prior to enrollment; (3) received within 30 days prior to screening or plans to receive during the study any of the following: cidofovir, or any investigational anti-cmv therapy or biological agent; (4) has severe hepatic insufficiency (defined as child-pugh class c; (5) has serum aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 5 xthe upper limit of normal (uln) or serum total bilirubin \> 2.5 x uln. (6) has end-stage renal impairment with a creatinine clearance less than 10 ml/min. (7) has both moderate hepatic insufficiency and moderate renal insufficiency; (8) uncontrolled infection at enrollment; (9) requires mechanical ventilation or is hemodynamically unstable at the time of enrollment; (10) has documented positive results for human immunodeficiency virus antibody (hivab), hepatitis c virus antibody (hcv-ab) with detectable hcv rna, or hepatitis b surface antigen (hbsag) within 90 days prior to enrollments; (11) has active solid tumor malignancies with the exception of localized basal cell or squamous cell skin cancer or the condition under treatment (e.g., lymphomas). (12) suffering from mental disorders or other conditions and unable to cooperate with the requirements of study treatment and monitoring; (13) unable or unwilling to sign the consent form; (14) pregnant or lactating women; (15) patients with other special conditions assessed as unqualified by the investigator
description of chronic pain in emergencies room and medical care modalities

Conditions: Chronic Pain; Emergency Department

Summary: the rate of patients with chronic pain (cp) is 40% in patients with acute pain in emergency department (ed). patients with cp come more frequently to ed than patients without cp. reasons for their visit to ed are often in relation with this cp. few studies have been interested to management modalities of these patients in ed. the investigators are going to realize a prospective observational study in one center. the hypothesis is that patients with chronic pain are less satisfied of ed management that patients without cp.

chronic pain is defined by a daily pain since more than 3 months. cp is different of acute pain because of their mechanisms, treatments and therapeutic objectives. cp is associated with an alteration of quality of life with psychological, social and economic consequences. the prevalence of cp in france is 15%. in ed, the rate of cp in patients with acute pain was around 40%. patients with cp come more frequently to ed than patients without cp. their use of care structures, particularly ed, is all the more frequent that their disability is important. the satisfaction of these patients in ed is associated with age, nature of pain, wait duration, realisation of imaging, and administration of painkillers and relieving of pain. the reasons why these patients go to ed were pain exacerbation, inadequate strategy of coping, severity of disease and sometime despair associated with stress or anxiety. currently the investigators do not know if these managements in ed are adequate or not. and finally the investigators do not know whether the satisfaction about their ed management is different from patients without cp. the investigators are going to collect data about all patients admitted in ed with the objective to compare the satisfaction between patients with cp and patients without cp. the follow up will be restricted to the area of ed. the last data will be collected just before the exit from ed.

Eligibility criteria:
inclusion criteria: * 18 years old or more admitted in ed * between 8 am and 5pm * from monday to friday. exclusion criteria: * patients admitted directly in emergency intensive care for vital distress defined by hemodynamic, respiratory, or neurological failure distress, * multitrauma patients; * patient without possibility to communicate because of neurologic disease or mental status disease; * linguistic barrier.

Keywords: chronic pain emergency satisfaction
changes in gut hormones, body composition and energy expenditure after roux-en-y

Conditions: Obesity; Weight Loss

Summary: the purpose of this study is to gain a better understanding of the mechanism of weight regain through gut hormone (substances in the gut that control various functions of the digestive organs) and energy expenditure (the amount of energy a person uses to complete bodily activities). our hypothesis is that gut hormone response might be different among subjects who are able to maintain weight loss and subjects with weight regain. for this study, investigators will measure fasting and postprandial (happening after a meal) gut hormones, bile acid, amino acids, vitamin b, vitamin d, myokines and adipokine levels in obese individuals who are at least 2 years after a roux-en-y gastric bypass (rygb). investigators will also measure resting metabolic rate (rmr) (the amount of energy expended daily) and body composition (the proportion of fat, muscle, and bone of an individual's body). the subjects body composition will be analyzed, including fat mass and fat free mass, by a dual-energy x-ray absorptiometry (dexa). this study will provide more information regarding the effect of rygb on gut hormones, adipokines, bile acids, amino acids, and energy expenditure and body compositions.


Eligibility criteria:
inclusion criteria: 1. age between 18-65 years of age 2. ability and willingness to provide informed consent exclusion criteria: 1. surgical/anatomical failure such as pouch enlargement, anastomosis dilation, formation of a gastrogastric fistula, 2. currently on medication that might affect weight gain including glp-1 analog 3. inability to provide informed written consent. 4. any known history of abnormal thyroid function. 5. females who are pregnant.

Keywords: weight regain sustain weight loss weight loss gut hormones
cryoballoon ablation of pulmonary veins after failed rf ablation in patients with paroxysmal af

Conditions: Paroxysmal Atrial Fibrillation

Summary: the aim of this prospective randomized double-blind study was to compare the efficacy and safety of cryoballoon ablation with the rf approach in the treatment of paroxysmal af after failed first radiofrequency ablation.


Eligibility criteria:
inclusion criteria: * previous failed first radiofrequency ablation procedure (only circumferential pv isolation without linear lesions) in patients referred for second catheter ablation of af * \> 3 months after first pvi exclusion criteria: * congestive heart failure * ejection fraction \<35% * left atrial diameter \>60 mm
resistive diaphragmatic breathing exercise with pursed lips breathing exercise in sub-acute stroke patients

Conditions: Stroke, Ischemic

Summary: to determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve pulmonary function in sub-acute ischemic stroke, to determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve trunk control in sub-acute ischemic stroke, to determine whether resistive diaphragmatic breathing exercise with pursed lips breathing exercise improve functional capacity in sub-acute ischemic stroke


Eligibility criteria:
inclusion criteria * age 40-65 years * onset of ischemic stroke in first two week * first episode of unilateral stroke with hemiparesis during previous 12 months * patient with no serious cognitive deficits i-e mini-mental state examination (score \>22) ability to understand, perform and follow simple verbal instructions * functional ambulation category (fac) \>3 * 6 min walk test distance should be \>200 m exclusion criteria: * known case of cardiopulmonary disease, bp \> 180/100 mmhg twice in 24 hours * known case of neurological disease other than stroke, known case of orthopedic disease i-e funnel chest, rib fractures or any other orthopedic deformity * medication that would influence metabolic or cardiorespiratory responses to exercise impaired level of consciousness, evidence of gross cognitive impairment.